Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
May 22, 2023 17:37 ET
|
Icosavax, Inc.
– IVX-A12 induced robust immune responses at Day 28 to both RSV and hMPV in older adults – – IVX-A12 was generally well tolerated with no vaccine-related SAEs – – First demonstration of hMPV...
Icosavax Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 10, 2023 16:05 ET
|
Icosavax, Inc.
- IVX-A12 (RSV+hMPV) Phase 1 topline interim data expected in 2Q 2023 - - Initiation of IVX-A12 Phase 2 trial expected in 2H 2023 - - Cash and cash equivalents, restricted cash, and short-term...
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 30, 2023 16:05 ET
|
Icosavax, Inc.
- FDA granted Fast Track Designation for IVX-A12, a bivalent respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) VLP vaccine candidate - - Completed dosing in ongoing Phase 1 study of...
Icosavax to Participate in the Upcoming Healthcare Conferences
February 28, 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Granted FDA Fast Track Designation for IVX-A12
February 21, 2023 08:00 ET
|
Icosavax, Inc.
SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
January 06, 2023 08:00 ET
|
Icosavax, Inc.
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase 1 study of...
Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
December 13, 2022 16:05 ET
|
Icosavax, Inc.
- In new data from Phase 1/1b study, IVX-121 showed sustained immunologic response at six months; geometric mean titers (GMT) against RSV-A through day 180 persisting at 64-98% of the GMTs at day 28...
Icosavax to Participate in the Evercore ISI HealthCONx Conference
November 22, 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...
Icosavax Reports Third Quarter Financial Results and Provides Corporate Update
November 14, 2022 16:05 ET
|
Icosavax, Inc.
- Initiated a Phase 1 trial of Icosavax’s first combination bivalent vaccine candidate, IVX-A12, against respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) in older adults - - IVX-A12...
Icosavax to Participate in in Upcoming Investor Conferences
November 08, 2022 08:00 ET
|
Icosavax, Inc.
SEATTLE, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines...